文献速递核素与放射性配体治疗放射性药物与辐射防护

面向患者的基于SPECT/CT的放射性药物分布可追溯定量研究

Toward a Patient-Specific Traceable Quantification of SPECT/CT-Based Radiopharmaceutical Distributions.
PubMed 文献 · J Nucl Med · 2021-11-18

本研究提出一种设计单腔体模的方法,通过内部不同体积分数的填充结构模拟非均匀空间活度分布,并基于一例转移性去势抵抗性前列腺癌患者的增强CT设计三个患者特异性肾脏体模进行验证。结果显示体模与制造体模一致性良好,SPECT图像中未见内部填充结构,但直方图分析提示患者实际活度分布比模型假设的两室模型更复杂。该方法为患者特异性评估放射性药物摄取提供了可能,可减少内照射剂量学的不确定性和个体化治疗的不确定性。

要点

  • 采用不同体积分数的内部填充结构设计单腔体模,可模拟非均匀空间活度分布。
  • 基于患者增强CT设计三个患者特异性肾脏体模,使用不同壁厚的gyroid结构重现肾髓质和皮质活度分布。
  • 直方图分析提示患者实际活度分布比模型假设的两室模型更复杂。

核心结论

  • 所提出的方法提供了患者特异性体模,可模拟非均匀活度分布,同时使用单一储备溶液,从而简化填充过程并减少活度测定的不确定性。
  • 该方法为患者特异性评估放射性药物摄取提供了前所未有的可能性,可减少内照射剂量学的不确定性和个体化治疗的不确定性。

研究设计与样本

  • 设计了一系列具有不同填充结构的体模,进行三维打印并测量。
  • 在简单几何结构中评估该方法的可行性后,基于一例转移性去势抵抗性前列腺癌患者的增强CT扫描设计了一组三个患者特异性肾脏体模。
  • 在肾髓质和皮质中使用不同壁厚的内部gyroid结构,以重现注射177Lu标记的前列腺特异性膜抗原后24小时治疗性SPECT/CT采集所观察到的非均匀活度分布(表观活度浓度比为1:1、1:3.5和1:7.5)。
  • 三维打印后进行了SPECT/CT实验,并将结果与患者数据在不同重建设置(迭代次数、子集数和后滤波)下进行比较。

主要发现

  • 体模设计与制造体模之间(基于高分辨率CT)发现良好一致性。
  • 在任何SPECT图像中均未见内部填充结构,表明特征尺寸足够小。
  • 对于某些填充结构和重建组合,实现了良好的视觉和定量一致性,但直方图分析提示患者实际活度分布比模型假设的两室模型更复杂。

局限性

  • 直方图分析提示患者实际活度分布比模型假设的两室模型更复杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Quantitative SPECT/CT imaging is currently the state of the art for peritherapeutic monitoring of radiopharmaceutical distributions. Because of poor resolution, however, the verification of SPECT/CT-based activity distributions is of particular importance. Because of the lack of a ground truth in patient measurements, phantoms are commonly used as a substitute for clinical validation of quantitative SPECT/CT. Because of the time-consuming and erroneous preparation of multicompartment phantoms, such as for the kidney, the usually very complex internal activity distributions are typically replaced by 1- or 2-compartment models. To provide a simplified solution for generating inhomogeneous activity distributions, this work presents a methodology for designing single-compartment phantoms that mimic inhomogeneous spatial activity distributions by using internal filling structures of different volume fractions. Methods: A series of phantoms with different filling structures was designed, 3-dimensionally printed, and measured. After assessing the feasibility of the presented approach in a simple geometry, a set of three patient-specific kidney phantoms was designed on the basis of the contrast-enhanced CT scan of a patient with metastatic castration-resistant prostate cancer. Internal gyroid structures of different wall thicknesses were used in the renal medulla and cortex to reproduce the inhomogeneous activity distribution observed in a peritherapeutic SPECT/CT acquisition 24 h after injection of 177Lu-labeled prostate-specific membrane antigen (apparent activity concentration ratios of 1:1, 1:3.5, and 1:7.5). After 3-dimensional printing, SPECT/CT experiments were performed and the results were compared with the patient data for different reconstruction settings (iterations, subsets, and postfiltering). Results: Good agreement was found between phantom designs and fabricated phantoms (based on high-resolution CT). No internal filling structures were visible in any of the SPECT images, indicating a sufficiently small feature size. Although good visual and quantitative agreement was achieved for certain combinations of filling structure and reconstruction, a histogram analysis indicated an even more complex activity distribution in the patient than represented by the two compartments assumed in our model. Conclusion: The proposed methodology provides patient-specific phantoms mimicking inhomogeneous activity distributions while using a single stock solution, thus simplifying the filling process and reducing uncertainties in the activity determination. This method enables an unprecedented possibility for patient-specific evaluation of radiopharmaceutical uptake, reducing uncertainties in internal dosimetry and individualized treatments.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Theisen AL, Lassmann M, Tran-Gia J, et al. Toward a Patient-Specific Traceable Quantification of SPECT/CT-Based Radiopharmaceutical Distributions. J Nucl Med. 2021. PMID: 34795011. doi:10.2967/jnumed.121.262925

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。